HAEMATO AG: 2016: Temporary IFRS results

Schönefeld (pta007/17.03.2017/07:30 UTC+1) HAEMATO AG Corporate News:

2016: Temporary IFRS results, turnover increased by 20% to Eur275.6m, EBIT (operating result) increased by 63% to Eur13.4m; the annual net profit in-creased by 94% to Eur10.7m

In 2016, HAEMATO AG, Berlin (ISIN: DE0006190705), achieved an IFRS group turnover of Eur275.6m (previous year: Eur229.7m), an operating result (EBIT) of Eur13.4m (previous year: Eur8.2m), and an annual net profit of Eur10.7m (previous year: Eur5.5m). Due to the positive business performance and a reduction in loans and barrowings, the company ended 2016 with a net debt position of Eur16.3m (prior year: Eur31.4m) and liquid assets Eur9.8m (previous year: Eur2.4m) based on the preliminary results.

"In 2016, the HAEMATO Group achieved the highest turnover and profit in company history. This allows us to be optimistic regarding the further development in 2017.

The results situation allows me to propose at the annual general meeting a dividend of Eur0.30 per share, which is the same amount as last year.

During the first eleven months of 2016, sales in the German pharmaceutical market grew by approx. 4.1%. However, selected preparation groups for cancer therapy grew by 17-22% in 2016. HAEMATO achieved 60% of its turnover in the field of oncology and is able to handle the special growth opportunities in these indications with chronic therapy well.

The demographic development is a key challenge facing the medical care industry. The ageing society in Germany (and throughout Western Europe) that is characterised by a structural shift towards more older and multi-morbid people - as well as the chronification of diseases caused by lifestyle and diet - forces health care policy to find sustainable solutions. In addition to increasing income and medical progress, the ageing of the society is a main reason for the health expenditure increase.

HAEMATO always strives to make a contribution towards keeping health care affordable," states Dr Christian Pahl, CEO of HAEMATO AG.

About HAEMATO:

HAEMATO AG, which was founded in 1993, is a pharmaceutical company. The focus of the operational activities is on the growth markets of patent-free and patent-protected pharmaceuticals. Focal points are therapies of cancer, HIV, and other chronic diseases.

(end)

Emitter:	HAEMATO AG Lilienthalstraße 5c 12529 Schönefeld Germany
Contact Person:	Dr. Christian Pahl
Phone:	+49 30 8973086-70
E-Mail:	ir@haemato.de
Website:	www.haemato.de
ISIN(s):	DE0006190705 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate